Skip to content

Maximum Protein Expression

Harness the power of Ubiquitous Chromatin Opening Element (UCOE) technology with the experience and expertise of Cobra’s cell line development team, and the added benefit of the Ambr™ robotic system.

Advantages of maxXpress

  • MaxXpress enables rapid production of gram quantities of recombinant proteins
  • Assesses up to 9 constructs at a time
  • Generates purified mixed clonal pool material in 6-10 weeks
  • Ensures efficient expression, independent of chromosomal integration
  • Evaluated for recombinant antibodies, secreted and intracellular proteins
  • Eliminates the need to screen 1,000s of clones
  • Unique mechanism that prevents gene silencing through effects on chromatin structure
Maximum Protein Expression

The maxXpress service combines Cobra’s cell line development team with UCOE technology to provide a rapid solution to producing monoclonal antibodies and recombinant proteins from CHO-S cells.

UCOE containing vectors have been shown to markedly enhance the expression of a wide variety of intracellular, secreted and membrane-bound proteins. Inclusion of a UCOE (4-8 kb in size) in a eukaryotic expression vector permits efficient expression in the vast majority of stable clones, whereas with conventional vectors only a minor proportion of transfectants demonstrate high-level expression. There is therefore no need for amplification and expression has been demonstrated to be stable over 130 generations. The combination of UCOE and CHO-S allows the generation of high yields of recombinant proteins.


Rapid and high-yielding production of correctly folded and glycosylated proteins, particularly for mammalian protein production:

  • Antibodies
  • Biosimilars
  • Therapeutic recombinant proteins
  • Vaccines
  • Diagnostics

Get In Touch

Speak to a member of our expert team and arrange to take a tour of our GMP facilities in the UK and Sweden

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.